These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33719143)

  • 1. Investigation of prevalence of biologic use and discontinuation rates in moderate-to-severe psoriasis patients in Newfoundland and Labrador using real-world data.
    Gulliver SR; Gulliver W
    Dermatol Ther; 2021 May; 34(3):e14944. PubMed ID: 33719143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Investigation of Comorbid Disease and Health Service Utilization Among Patients With Moderate to Severe Psoriasis in Newfoundland and Labrador.
    Gulliver WP; Randell S; Gulliver S; Macdonald D; Gregory V; Nagle S; Chambenoit O
    J Cutan Med Surg; 2019; 23(1):29-34. PubMed ID: 30041544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do Biologics Protect Patients With Psoriasis From Myocardial Infarction? A Retrospective Cohort.
    Gulliver WP; Randell S; Gulliver S; Connors S; Bachelez H; MacDonald D; Gladney N; Morrissey A; Fleming P
    J Cutan Med Surg; 2016 Nov; 20(6):536-541. PubMed ID: 27207347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.
    Doshi JA; Takeshita J; Pinto L; Li P; Yu X; Rao P; Viswanathan HN; Gelfand JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1057-1065.e4. PubMed ID: 26946986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016.
    Carretero Hernández G; Ferrándiz C; Rivera Díaz R; Daudén Tello E; de la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Belinchón Romero I; López-Estebaranz JL; Alsina Gibert M; Sánchez-Carazo JL; Ferrán Farrés M; González Quesada A; Carrascosa Carrillo JM; Llamas-Velasco M; Mendiola Fernández MV; Ruiz Genao D; Muñoz Santos C; García-Doval I; Descalzo MA;
    Actas Dermosifiliogr (Engl Ed); 2018 Sep; 109(7):617-623. PubMed ID: 29887167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
    Belinchón I; Ramos JM; Carretero G; Ferrándiz C; Rivera R; Daudén E; De la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Sánchez-Carazo JL; López-Estebaranz JL; Alsina M; Ferrán M; Torrado R; Carrascosa JM; Llamas-Velasco M; Ortiz PL; García-Doval I; Descalzo MA;
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1700-1708. PubMed ID: 28485816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real World Studies of Psoriasis and Mental Illness in Newfoundland and Labrador.
    Badaiki W; Penney M; Pyper E; Lester K; Skeard J; Shin J; Fisher B; Gulliver S; Gulliver W; Rahman P
    J Cutan Med Surg; 2022; 26(5):494-501. PubMed ID: 35938546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study.
    Iannone LF; Bennardo L; Palleria C; Roberti R; De Sarro C; Naturale MD; Dastoli S; Donato L; Manti A; Valenti G; D'Amico D; D'Attola S; De Francesco AE; Bosco V; Donato Di Paola E; Nisticò SP; Citraro R; Russo E; De Sarro G
    PLoS One; 2020; 15(11):e0241575. PubMed ID: 33141869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies.
    Levin AA; Gottlieb AB; Au SC
    J Drugs Dermatol; 2014 Jul; 13(7):848-53. PubMed ID: 25007369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.
    Lin PT; Wang SH; Chi CC
    Sci Rep; 2018 Oct; 8(1):16068. PubMed ID: 30375427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM).
    Sbidian E; Mezzarobba M; Weill A; Coste J; Rudant J
    Br J Dermatol; 2019 Jan; 180(1):86-93. PubMed ID: 29791721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Menter A; Papp KA; Gooderham M; Pariser DM; Augustin M; Kerdel FA; Fakharzadeh S; Goyal K; Calabro S; Langholff W; Chavers S; Naessens D; Sermon J; Krueger GG
    J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1148-58. PubMed ID: 27027388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
    JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.
    Papp KA; Gooderham M; Beecker J; Lynde CW; Delorme I; Dei-Cas I; Albrecht L; Rampakakis E; Sampalis JS; Vieira A; Hussein S; Chambenoit O; Rihakova L
    BMC Dermatol; 2019 Jun; 19(1):9. PubMed ID: 31226985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis.
    Mourad A; Straube S; Armijo-Olivo S; Gniadecki R
    Br J Dermatol; 2019 Sep; 181(3):450-458. PubMed ID: 30729500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
    Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MACEs Not Associated With the Use of Biologic Therapy for Psoriasis in Real-World Clinical Practice: A Canadian Multicenter Retrospective Study.
    Kim WB; Qiang J; Yeung J
    J Cutan Med Surg; 2016 Jul; 20(4):352-3. PubMed ID: 26842812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.